Current Funding Opportunities

To visit the NCI grant site, click here


Use your device's search function to find a specific disease or funding source. 


Breast 


Avon Breast Cancer Crusade 2017 Funding 

These research initiative funds translational research using clinical studies, human cell culture, epidemiologic, and other progressive approaches to understand the causes of breast cancer and develop new treatments.


Access to Care - Breast Health Outreach Program

Supports community-based organizations to educate the public on the importance of good breast health and link underserved women to appropriate breast health services. Range from $25,000-$80,000 per year. 

Application Deadline: August 17, 2017



Access to Care - Support Services Program

Supports programs providing services and education to women and men diagnosed with breast cancer, including nutrition support, counseling and referral programs, financial assistance programs, and information services. Application is by invitation only. To seek an invitation, please send a description of the proposed program to grants@avonbcc.org.


Department of Defense Breast Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2017

FY17 BCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2017.  Pre-application and application deadlines will be available when the Program Announcements are released. Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  

Breakthrough Award
• Investigators at all academic levels (or equivalent)
Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged to apply under Funding Levels 1 and 2

Funding Level 1:  Innovative, high-risk/high-reward research that is in the earliest stages of idea development.  Research with potential to yield new avenues of investigation.  Proof of concept.  No preliminary data required.
Funding Level 2:  Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation.
Funding Level 3:  Advanced translational studies that have potential for near-term clinical investigation.  Small-scale clinical trials may apply.
Funding Level 4:  Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer.  Near-term clinical impact is expected. Human clinical testing is required. PIs are expected to have experience in successfully leading large-scale projects

Breakthrough Fellowship Award
As of the application submission deadline, all eligible PIs must have:
• Successfully completed the requirements for a doctoral or medical degree, and 
• Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and 
• A total of less than 4 years experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

Era of Hope Scholar Award
Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

Innovator Award
Associate Professor or above (or equivalent).

Distinguished Investigator Award
Assistant Professor or above (or equivalent) and more than 6 years beyond the PI’s last training position as of the application submission deadline

Colorectal


Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) 


This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.  
 

Application Due Date: Application Receipt/Submission Date(s): August 15, 2017; February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.

 

Lung 

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) 

 
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.  
 

Application Due Date: Application Receipt/Submission Date(s): August 15, 2017; February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.


Learn More>>



 
Stand Up To Cancer – LUNGevity – American Lung Association Lung Cancer Interception Dream Team

This grant will provide up to $7 million to solve key problems in lung cancer interception research.  LUNGevity Foundation is the leading lung cancer-focused private funder of research in the United States, with a programmatic focus on early detection. The American Lung Association is the country’s leading organization working to improve lung health and prevent lung disease.  Specifically involved is LUNG FORCE, a Lung Association initiative that seeks to unite the nation in defeating lung cancer.

Letter of Intent Due: March 8, 2017

Melanoma


Roslyn and Jerome Meyer Pilot Awards for Research in Melanoma and Immuno-Oncology

Yale Cancer Center in collaboration with the Yale SPORE in Skin Cancer invites applications for funding of two-year research projects focusing on further study of the tumor immune microenvironment in melanoma and biology of melanoma with potential to provide the rationale for novel therapeutic applications. 

Each of the three successful grant applications will receive $44,000 per year x 2 years. Receipt of year 2 funds will be based on adequate progress in year 1. Progress reports will be required at the end of the year 1 and the 2-year funding period. All funds will be directed to supplies or salary. Applicants must have full time faculty appointments (including research faculty).  

Application Deadline: April 1, 2017. Contact edward.kaftan@yale.edu with any questions. 



Ovarian

Department of Defense Ovarian Cancer Research Program Funding Opportunities

FY17 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in February 2017.  Pre-application and application deadlines will be available when the Program Announcements are released. 

Clinical Development Award
Must be an independent investigator at or above the level of Assistant Professor (or equivalent)

Investigator-Initiated Research Award
Must be an independent investigator at or above the level of Assistant Professor (or equivalent)

Ovarian Cancer Academy Award – Early-Career Investigator
Must be within 3 years of his/her last postdoctoral research position (Ph.D) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline.  A letter attesting to eligibility is required.

Pilot Award
Established Investigator:  Independent investigator for whom it has been more than 3 years since his/her last postdoctoral research position (Ph.D) or clinical fellowship (M.D.), or equivalent; or
Early-Career Investigator:  Investigators must meet one of the following criteria by the application submission date: Must be within 3 years of his/her last postdoctoral research position (Ph.D) or clinical fellowship (M.D.) OR In a postdoctoral research position (Ph.D), or clinical fellowship (M.D.), or equivalent.  

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  


Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) 


This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.  
 

Application Due Date: Application Receipt/Submission Date(s): August 15, 2017; February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.

 

Pancreatic

Pancreatic Cancer Action Network/AACR 2017 Research Grants Program

The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network are pleased to announce the opening of the 2017 Research Grants Program to support early-career investigators focused on pancreatic cancer.

Two grant mechanisms, the Pathway to Leadership Grant and the Career Development Award, are being offered for postdoctoral and clinical research fellows or junior faculty, respectively. Submissions for 2017 grants must be completed online using the proposalCENTRAL website. Funding decisions will be announced in the spring, and the grant term will begin July 1, 2017. The recipients will be honored at the AACR Annual Meeting 2017, to be held in Washington, D.C., April 1-5, 2017. 


SU2C-Lustgarten Foundation Pancreatic Cancer Interception Dream Team

This grant will provide up to $7 million over a four-year term to advance innovative approaches to intercept the disease-causing process.  The Lustgarten Foundation, based in Bethpage, N.Y., is the largest private funder in the U.S. of pancreatic cancer research.  The new team will be the fifth SU2C Team supported by the Lustgarten Foundation, bringing its total investment in SU2C research to $17,520,000. 

Letter of Intent Due: March 22, 2017

The Pancreatic Cancer Detection Consortium (U01)

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions.

Application Due Dates: May 26, 2017; September 21, 2017, April 6, 2018

Learn More>>

Alliance for Cancer Gene Therapy

Investigator’s Award in Clinical Translation of Cell and Gene Therapy for Cancer

A number of cell and gene therapy approaches for cancer have been shown to be efficacious and safe in laboratory animal models in the recent years, but their translation into clinical trials has been hindered by a lack of resources. Recognizing this critical need, ACGT is accepting grant applications to produce and release-testing of the clinical trial agents under cGMP, conduct the necessary pre-clinical pharmacological and toxicological studies in appropriate animal models, and/or conducting the clinical translational trials in patients in support of an Investigative New Drug (IND) application to the FDA. 

LOI Due: March 21, 2017 

Learn More>>

AVON 

Avon Breast Cancer Crusade 2017 Funding 

These research initiative funds translational research using clinical studies, human cell culture, epidemiologic, and other progressive approaches to understand the causes of breast cancer and develop new treatments.


Access to Care - Breast Health Outreach Program

Supports community-based organizations to educate the public on the importance of good breast health and link underserved women to appropriate breast health services. Range from $25,000-$80,000 per year. 

Application Deadline: August 17, 2017



Access to Care - Support Services Program

Supports programs providing services and education to women and men diagnosed with breast cancer, including nutrition support, counseling and referral programs, financial assistance programs, and information services. Application is by invitation only. To seek an invitation, please send a description of the proposed program to grants@avonbcc.org.


NIH/NCI


Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) and (R21)

This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival.


Examination of Survivorship Care Planning Efficacy and Impact (R21) and (R01)


The purpose of these Funding Opportunity Announcements (FOAs) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest.

Application Receipt/Submission Date(s): Multiple dates, see here




Emerging Questions in Cancer Systems Biology (U01)

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for Research Projects that utilize systems biology approaches to address emerging questions in cancer initiation, progression, and treatment.

Application Receipt/Submission Date(s): June 23, 2017; November 24, 2017; June 22, 2018; November 23, 2018, by 5:00 PM local time of applicant organization.

Learn More>>


Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)

This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem.

Expiration date: January 8, 2018

Learn More>>


Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) 


The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy.

Application Due Dates: July 14, 2017; December 14, 2017 

Learn More>> 



Multilevel Interventions in Cancer Care Delivery: Building from the Problem of Follow-up to Abnormal Screening Tests (U01)

This Funding Opportunity Announcement (FOA) encourages applications that strengthen the science of multilevel effects of cancer care interventions by addressing the problem of incomplete follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers.

Application Due Dates: May 26, 2017; September 21, 2017

Learn More>> 


The Pancreatic Cancer Detection Consortium (U01)

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions.

Application Due Dates: May 26, 2017; September 21, 2017, April 6, 2018

Learn More>>


Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01)

This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Application Receipt/Submission Date(s): May 30, 2017; November 30, 2017; May 30, 2018; November 30, 2018, by 5:00 PM local time of applicant organization.

Learn More>>


Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for  developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers.

Application Due Dates: January 29, 2018

Learn More>> 


Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25)

To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

Learn More>>


Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25)

Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, as well as the cause and reduction of cancer health disparities in accordance with the overall mission of the NCI.  

Application Receipt/Submission Date(s): Standard Dates apply.  

Learn More>> 


Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)
This funding opportunity announcement (FOA) invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research.

Application Receipt/Submission Date(s): March 22, 2017; July 19, 2017; November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018, by 5:00 PM local time of applicant organization.

Learn More>>

Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology (R21)
This Funding Opportunity Announcement (FOA) encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer.

Application Receipt/Submission Date(s): March 22, 2017; July 19, 2017; November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018, by 5:00 PM local time of applicant organization.

Learn More>>

Clinical and Translational Exploratory/Developmental Studies (R21)
This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

Application Receipt/Submission Date(s): March 22, 2017; July 19, 2017; November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018, by 5:00 PM local time of applicant organization.

Learn More>> 

Cancer Moonshot Related FOAs

Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative R01 projects from multi-disciplinary teams to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research. 

Application Deadline: March 5, 2017

Learn More>>

Canine Immunotherapy Trials and Correlative Studies (U01)

This Funding Opportunity Announcement (FOA) will support canine clinical studies using immunotherapeutic agents and novel drug combinations (such as immune modulators, molecular targeted agents, chemotherapy, and/or radiation) together with laboratory correlative studies that seek to describe characterize and understand the cellular and molecular mechanisms that determine the anti-tumor response (or non-response) in dogs with spontaneous tumors. 

Deadline for Application: March 7, 2017


Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)

This Funding Opportunity Announcement (FOA) will support a coordinating center for a network of cooperative agreements (see U01 FOA RFA-CA-17-001) that will conduct clinical trials in pet dogs with spontaneous tumors and perform laboratory correlative studies associated with the clinical trials.

Deadline for Application: March 7, 2017



Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the area of PDAC microenvironment with the ultimate goal of understanding the interaction between tumors and the microenvironment. 

Deadline for Application: March 7, 2017


Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)

This funding opportunity announcement (FOA) invites applications to establish a Resource Center (RC) for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (Consortium) that has the ultimate goal to design new immunotherapy and combination interventions in PDAC.

Deadline for Application: March 7, 2017


empty 
Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24)

This National Cancer Institute (NCI) funding opportunity announcement (FOA) solicits applications for multidisciplinary Cancer Immune Monitoring and Analysis Centers (CIMACs) that will serve as the main units of the Network for correlative studies in clinical trials involving immunotherapy. The Network will encompass two to three CIMACs (to be supported by this FOA) and a single Cancer Immunologic Data Commons (CIDC) (to be supported by the companion FOA, RFA-CA-17-006) forming a CIMACs-CIDC Network.

Deadline for Application: March 17, 2017


empty 
Cancer Immunologic Data Commons (CIDC) (U24)

The purpose of this funding opportunity announcement (FOA) is to solicit applications for establishment of a Cancer Immunologic Data Commons (CIDC) to provide bioinformatics support as part of a Network for correlative studies in clinical trials involving cancer immunotherapy. The Network will encompass a single CIDC award (to be supported by this FOA) and up to three Cancer Immune Monitoring and Analysis Centers (CIMACs) (to be supported by a companion FOA, RFA-CA-17-005).  

Application Deadline: March 17, 2017


 
Mechanisms of Cancer Drug Resistance and Sensitivity (U54)

The goal of this Funding Opportunity Announcement (FOA) is to create a network of Drug Resistance and Sensitivity Centers (DRSCs) to develop innovative strategies to study mechanisms of tumor resistance or sensitivity to anticancer therapy.  It is hoped that such studies will permit future efforts to identify and exploit these phenomena in clinical settings.

Deadline for Application: March 3, 2017


PDX Development and Trial Centers (PDTCs)(U54)

This funding opportunity announcement (FOA) solicits applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine.

Deadline for Application: March 3, 2017


Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer  (Admin Supp)

This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative.

Deadline for Application: March 28, 2017


Emerging Questions in Cancer Systems Biology (U01)

The National Cancer Institute (NCI) is sponsoring a new Cancer Systems Biology Consortium (CSBC) that includes U54 CSBC Research Centers (RFA-CA-15-014), a U24 CSBC Coordinating Center (RFA-CA-15-015) and, through this FOA, well-defined, discrete and circumscribed Research Projects addressing emerging problems in cancer. The CSBC initiative aims to address challenges in cancer research through the use of experimental biology or population science combined with in silico modeling, multi-dimensional data analysis, and systems engineering. 

Deadline for Application: June 23, 2017


Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp)

The National Cancer Institute (NCI) administers two unique programs focused on supporting technology development research that offer transformative potential for advancing cancer research. The Innovative Molecular Analysis Technologies (IMAT) program supports highly innovative, data-generating platforms and methodologies while the Informatics Technologies for Cancer Research (ITCR) program supports powerful data processing and visualization technologies.

Deadline for Application: April 12, 2017

Pancreatic Cancer Action Network

Pancreatic Cancer Action Network/AACR 2017 Research Grants Program

The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network are pleased to announce the opening of the 2017 Research Grants Program to support early-career investigators focused on pancreatic cancer.

Two grant mechanisms, the Pathway to Leadership Grant and the Career Development Award, are being offered for postdoctoral and clinical research fellows or junior faculty, respectively. Submissions for 2017 grants must be completed online using the proposalCENTRAL website. Funding decisions will be announced in the spring, and the grant term will begin July 1, 2017. The recipients will be honored at the AACR Annual Meeting 2017, to be held in Washington, D.C., April 1-5, 2017. 


The Pancreatic Cancer Detection Consortium (U01) 

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. 

Application Due Dates: May 26, 2017; September 21, 2017, April 6, 2018 

Learn More>>

Schwartz Center

National Compassionate Caregiver of the Year Award

The National Compassionate Caregiver of the Year (NCCY) Award is a national recognition program that elevates excellence in compassionate healthcare. Since 1999, the Schwartz Center for Compassionate Healthcare has honored outstanding healthcare professionals who display extraordinary devotion and compassion in caring for patients and families. The award recognizes those who make a profound difference through their unmatched dedication to compassionate, collaborative care.

Deadline for Nominations: March 31, 2017

Learn More>>

SU2C


LUNGevity – American Lung Association Lung Cancer Interception Dream Team

This grant will provide up to $7 million to solve key problems in lung cancer interception research.  

Letter of Intent Due: March 8, 2017



Lustgarten Foundation Pancreatic Cancer Interception Dream Team

This grant will provide up to $7 million over a four-year term to advance innovative approaches to intercept the disease-causing process.  
 
Letter of Intent Due: March 22, 2017


V Foundation

Translational Cancer Research Grant

The V Foundation seeks to support translational research projects within the scope of all types of cancers. The Translational Research Award is a $600,000 grant awarded in three annual installments of $200,000. Indirect costs up to a maximum of 10% within the total award are permitted.

If you would like to be considered for nomination, please submit a 1 page summary of your proposed project and a copy of your CV to edward.kaftan@yale.edu by February 21st.  If selected for nomination, the full application would be due May 2nd.


Other


Innovative Molecular Analysis Technologies (IMAT) Program – related announcements:  
These announcements are in advance of the formal FOA to allow for planning your submissions.  FOA is expected in December with an expected application submission deadline in February 2016.  
• Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Molecular and Cellular Analysis Technologies for Cancer Research (R21)
National Cancer Institute
• Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Emerging Molecular Analysis Technologies for Cancer Research (R33) 
National Cancer Institute
• Notice of Intent to Publish a Funding Opportunity Announcement for Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) 
National Cancer Institute
• Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Development and Validation of Technologies for Cancer-Relevant Biospecimen Science (R33)
National Cancer Institute

The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants. 

Click to see all the Internal Grants from 2012-2016

Next round of applications for the Program in Innovative Therapeutics for Connecticut's Health (PITCH) due March 15

The Program in Innovative Therapeutics for Connecticut’s Health (PITCH) fuels target validation based on innovative research ideas born in laboratories from Yale University and the University of Connecticut. With a grant from the State of Connecticut’s Bioscience Innovation Fund, this three-year, $10 million dollar program provides translational research resources to generate prototype therapeutics that address unmet clinical needs. 

Deadline: March 15. Link to application attached and here: http://pitch.yale.edu/application.

Please contact Jane Merkel for more information, janie.merkel@yale.edu

Yale Cancer Center 2017 Internal Pilot Grant Program

Yale Cancer Center is pleased to announce the 2017 Internal Pilot Grant competition. These grants will support innovative basic, clinical, computational, prevention/control, and translational cancer research. The primary review criteria will be scientific excellence, innovation, cancer relevance, and the likelihood of the project evolving into federally funded cancer research. Members of Yale Cancer Center or faculty who have applied for membership are eligible to apply. The anticipated start date for funding is May 1, 2017.

Deadline for Submission: March 9, 2017 Grant application forms and guidelines may be obtained by email from Jan Zulkeski (janice.zulkeski@yale.edu)


Yale Cancer Center 2017 Internal Collaborative (Co-Pilot) Grant Program

Yale Cancer Center is pleased to announce the 2017 Internal Co-Pilot Grant competition. These grants will support innovative basic, clinical, computational, prevention/control, and translational cancer research. The primary review criteria will be scientific excellence, innovation, cancer relevance, and the likelihood of the project evolving into federally funded cancer research. Members of Yale Cancer Center or faculty who have applied for membership are eligible to apply. 

Letter of Intent Due: April 3, 2017 to be emailed to Jan Zulkeski (janice.zulkeski@yale.edu)


Roslyn and Jerome Meyer Pilot Awards for Research in Melanoma and Immuno-Oncology

Yale Cancer Center in collaboration with the Yale SPORE in Skin Cancer invites applications for funding of two-year research projects focusing on further study of the tumor immune microenvironment in melanoma and biology of melanoma with potential to provide the rationale for novel therapeutic applications. 

Each of the three successful grant applications will receive $44,000 per year x 2 years. Receipt of year 2 funds will be based on adequate progress in year 1. Progress reports will be required at the end of the year 1 and the 2-year funding period. All funds will be directed to supplies or salary. Applicants must have full time faculty appointments (including research faculty).  

Application Deadline: April 1, 2017. Contact edward.kaftan@yale.edu with any questions. 



2016 Class of 61 YCC Research Award 

In order to recognize significant accomplishment and outstanding promise in cancer research, Yale Cancer Center is pleased to announce the opening of the competition for the 2016 Class of ’61 Yale Cancer Center Research Award. This annual Award recognizes significant accomplishment in cancer research at Yale University by a young member of the faculty, coupled with the expectation for future outstanding contributions to our understanding of the causes and cures for cancer.


YCCI Scholar Awards


We are pleased to announce a request for applications for YCCI Scholar Awards, which provide salary and/or research funds to a select number of junior faculty members who are strongly committed to careers in clinical research, community-based research or translational research.


Pew-Stewart Scholars Program for Cancer Research 

An internal competition for a new national grant program for recently appointed assistant professors to conduct cancer research. Assistant professors appointed after July 15, 2013 are eligible for consideration. 

SPORE in Skin Cancer Program Awards

Learn More>>
            

SPORE in Lung Cancer Program Awards

Learn More>>

LungSPORE@yale.edu     


Lion Heart Grants
  • Funding amount based on fundraising annually done by Lion Hearts
  • For Yale Cancer Center members only 
  • To support breast cancer research
  • Committee of Yale Cancer Center members and Lion Heart members review and select grant recipients
  • Administered by Anees Chagpar

V Foundation Pediatric Cancer Grants

  • ONE NOMINEE TO APPLY FOR EITHER THE V SCHOLAR OR TRANSLATIONAL AWARD
  • The nominee must be nominated by their Cancer Center Director if the research institution is a cancer center. If the research institution is not a cancer center, then the department chair or other senior research administrative official who is responsible for the internal nominee 
  • Applicant must be employed at a non-profit research institution 
  • Administered by Gary Kupfer  

American Cancer Society Institutional Research Grants

  • $30,000 for one year
  • For assistant professors only
  • Prior national research grant disqualifies
  • Four awards per year
  • Usually reviewed in December
  • Administered by Joann Sweasy


Rausch Foundation Grants in Community Health

  • $30,000-$50,000 for one year
  • Population science focus
  • Priority to projects with impact to New Haven
  • Administered by Melinda Irwin 


YCC Pilot Grants

  • $50,000 for one year
  • All YCC members eligible to apply
  • Specific project proposed by individual investigator
  • Seven or eight awards per year, distributed among all seven research programs
  • Usually reviewed in Spring
  • Administered by Joann Sweasy
  • RFAs will be posted in January 2017, along with other deadline information
  • For more information please contact Jan Zulkeski


T-TARE Award

  • Up to $200,000 for one year
  • For teams of investigators
  • Research with a translational focus
  • Major goal is to generate data and evidence of collaboration for multi-investigator grant application
  • Administered by Roy Herbst

Head and Neck Cancer T-TARE Award - July 1, 2016 - June 30, 2017


Yale Discovery Fund Grants

  • $450,000 to be spent over three years
  • High-risk/high-reward cancer research
  • Multidisciplinary collaborative research
  • Hope to fund 3 – 4 each year
  • Administered by Dan DiMaio


Leslie Warner Postdoctoral Fellowship

  • ~$42,000 for one year
  • Fellows working in YCC member laboratories eligible to apply
  • Must be in first year of fellowship
  • Four awards every other year
  • Usually reviewed in fall
  • Review organized by Karen Anderson